Oppenheimer Maintains Outperform on Moderna, Raises Price Target to $179
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Hartaj Singh maintains an Outperform rating on Moderna (NASDAQ:MRNA) and raises the price target from $163 to $179.
June 12, 2024 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Hartaj Singh has maintained an Outperform rating on Moderna and increased the price target from $163 to $179, indicating a positive outlook for the stock.
The increase in the price target from $163 to $179 by a reputable analyst suggests a positive outlook for Moderna's stock. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100